BioSpace News Archive

LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced that it has achieved CE Mark for the Amira System, its new testing system that provides low-cost, highly sensitive COVID-19 testing.

The world of dentistry continued to move ahead at a massive pace and is witnessing an increasing influx of advanced technologies.

Fact.MR, a Market Research and Competitive Intelligence Provider - The global bioabsorbable stents market is predicted to witness a moderate growth rate of 9.6% during the forecast years 2022 to 2032.

Wilmington, Delaware, United States: The increasing prevalence of metabolic disorders among people worldwide is projected to augment the growth of the global peptide therapeutics market.

Wilmington, Delaware, United States: Transparency Market Research has published a new report titled, ‘Electronic Health Records Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.

Sensorion is pleased to announce the participation in-person of a member of Sensorion’s senior management in the Gene Therapy Development and Manufacturing conference being held in London, UK, in June 2022.

POXEL SA announced that the U.S. Patent and Trademark Office has issued to Poxel US Patent No. 11319313 which represents a new patent for PXL065, a novel, proprietary deuterium-stabilized R-stereoisomer of pioglitazone.

MC2 Therapeutics A/S, a commercial stage pharmaceutical company, has named Lars Iversen, MD, DMSc an esteemed chair professor in dermatology at Aarhus University Hospital and at Aarhus University, its new full-time Chief Medical Officer as of October 1st, 2022.

Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces it has completed patient enrollment with more than 800 subjects randomized in the ENHANCE-1 trial, evaluating ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease.

Regulatory News: Disclaimer: Intended for international media and investor audiences only Ipsen announced that Dysport® has received positive opinion in Europe for the management of urinary incontinence in adults with neurogenic detrusor overactivity due to spinal cord injury or multiple sclerosis, who are regularly performing clean intermittent catheterization.